Teplizumab: The First Treatment to Delay the Progression of Type 1 Diabetes
Jennifer D. Goldman, Hailey Choi
Abstract
Clinical Pharmacology Updates| May 16 2023 Teplizumab: The First Treatment to Delay the Progression of Type 1 Diabetes Jennifer D. Goldman 0000-0002-9617-3998 ; Jennifer D. Goldman Massachusetts College of Pharmacy and Health Sciences, Boston, MA Corresponding author: Jennifer D. Goldman, [email protected] Search for other works by this author on: This Site PubMed Google Scholar Hailey Choi Hailey Choi Massachusetts College of Pharmacy and Health Sciences, Boston, MA Search for other works by this author on: This Site PubMed Google Scholar Corresponding author: Jennifer D. Goldman, [email protected] Clin Diabetes 2023;41(3):474–476 https://doi.org/10.2337/cd23-0033 PubMed: 37456101 Views Icon Views Article contents Figures & tables Video Audio Supplementary Data Peer Review Share Icon Share Facebook Twitter LinkedIn Email Cite Icon Cite Get Permissions Citation Jennifer D. Goldman, Hailey Choi; Teplizumab: The First Treatment to Delay the Progression of Type 1 Diabetes. Clin Diabetes 1 July 2023; 41 (3): 474–476. https://doi.org/10.2337/cd23-0033 Download citation file: Ris (Zotero) Reference Manager EasyBib Bookends Mendeley Papers EndNote RefWorks BibTex toolbar search Search Dropdown Menu toolbar search search input Search input auto suggest filter your search All ContentAll JournalsClinical Diabetes Search Advanced Search Type 1 diabetes is caused by autoimmune β-cell destruction leading to the need for management with life-sustaining insulin. Typically, people are diagnosed with type 1 diabetes based on clinical symptoms. Glucose and A1C levels, as well as autoantibodies, may rise well before clinical symptoms are seen. Three stages of type 1 diabetes have been identified. Until recently, these stages were primarily used for research purposes. Stage 1 is presymptomatic, and people in this stage have normoglycemia and the presence of two or more islet autoantibodies. Stage 2 is the presence of two or more autoantibodies with dysglycemia. Individuals in this stage are still presymptomatic. Stage 3 is the onset of symptomatic disease and is usually when diagnosis occurs. Although there is no cure for type 1 diabetes, there is now a treatment to delay the progression from stage 2 to stage 3 of the disease (1,2).... You do not currently have access to this content.